iScience (Dec 2023)
Global blood miRNA profiling unravels early signatures of immunogenicity of Ebola vaccine rVSVΔG-ZEBOV-GP
- Eleonora Vianello,
- Josefine Persson,
- Björn Andersson,
- Suzanne van Veen,
- Thomaz Lüscher Dias,
- Francesco Santoro,
- Malin Östensson,
- Ogonna Obudulu,
- Christopher Agbajogu,
- Sara Torkzadeh,
- Helder I. Nakaya,
- Donata Medaglini,
- Claire-Anne Siegrist,
- Tom H.M. Ottenhoff,
- Ali M. Harandi,
- Selidji Todagbe Agnandji,
- Rafi Ahmed,
- Jenna Anderson,
- Floriane Auderset,
- Philip Bejon,
- Luisa Borgianni,
- Jessica Brosnahan,
- Annalisa Ciabattini,
- Olivier Engler,
- Marielle C. Haks,
- Ali M. Harandi,
- Donald Gray Heppner,
- Alice Gerlini,
- Angela Huttner,
- Peter G. Kremsner,
- Donata Medaglini,
- Thomas Monath,
- Francis Ndungu,
- Patricia Njuguna,
- Tom H.M. Ottenhoff,
- David Pejoski,
- Mark Page,
- Gianni Pozzi,
- Francesco Santoro,
- Claire-Anne Siegrist,
- Selidji Todagbe Agnandji,
- Luisa Borgianni,
- Annalisa Ciabattini,
- Sheri Dubey,
- Micheal J. Eichberg,
- Olivier Engler,
- Patrícia Gonzalez-Dias,
- Paulin Ndong Essone,
- Ali M. Harandi,
- Alice Gerlini,
- Angela Huttner,
- Lumeka Kabwende,
- Peter Gottfried Kremsner,
- Donata Medaglini,
- Helder Nakaya,
- Sravya S. Nakka,
- Tom H.M. Ottenhoff,
- Mariëlle C. Haks,
- Josefine Persson,
- Gianni Pozzi,
- Sylvia Rothenberger,
- Francesco Santoro,
- Claire-Anne Siegrist,
- Suzanne van Veen,
- Eleonora Vianello
Affiliations
- Eleonora Vianello
- Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands; Corresponding author
- Josefine Persson
- Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Corresponding author
- Björn Andersson
- Bioinformatics Core Facility, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Suzanne van Veen
- Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands
- Thomaz Lüscher Dias
- Scientific Platform Pasteur-University of São Paulo, São Paulo, Brazil
- Francesco Santoro
- Department of Medical Biotechnologies, University of Siena, Italy
- Malin Östensson
- Bioinformatics Core Facility, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Ogonna Obudulu
- Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Christopher Agbajogu
- Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Sara Torkzadeh
- Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Helder I. Nakaya
- Hospital Israelita Albert Einstein, São Paulo, Brazil
- Donata Medaglini
- Department of Medical Biotechnologies, University of Siena, Italy
- Claire-Anne Siegrist
- Centre for Vaccinology, University Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland
- Tom H.M. Ottenhoff
- Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands
- Ali M. Harandi
- Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Vaccine Evaluation Center, BC Children’s Hospital Research Institute, University of British Columbia, Vancouver, Canada
- Selidji Todagbe Agnandji
- Rafi Ahmed
- Jenna Anderson
- Floriane Auderset
- Philip Bejon
- Luisa Borgianni
- Jessica Brosnahan
- Annalisa Ciabattini
- Olivier Engler
- Marielle C. Haks
- Ali M. Harandi
- Donald Gray Heppner
- Alice Gerlini
- Angela Huttner
- Peter G. Kremsner
- Donata Medaglini
- Thomas Monath
- Francis Ndungu
- Patricia Njuguna
- Tom H.M. Ottenhoff
- David Pejoski
- Mark Page
- Gianni Pozzi
- Francesco Santoro
- Claire-Anne Siegrist
- Selidji Todagbe Agnandji
- Luisa Borgianni
- Annalisa Ciabattini
- Sheri Dubey
- Micheal J. Eichberg
- Olivier Engler
- Patrícia Gonzalez-Dias
- Paulin Ndong Essone
- Ali M. Harandi
- Alice Gerlini
- Angela Huttner
- Lumeka Kabwende
- Peter Gottfried Kremsner
- Donata Medaglini
- Helder Nakaya
- Sravya S. Nakka
- Tom H.M. Ottenhoff
- Mariëlle C. Haks
- Josefine Persson
- Gianni Pozzi
- Sylvia Rothenberger
- Francesco Santoro
- Claire-Anne Siegrist
- Suzanne van Veen
- Eleonora Vianello
- Journal volume & issue
-
Vol. 26,
no. 12
p. 108574
Abstract
Summary: The vectored Ebola vaccine rVSVΔG-ZEBOV-GP elicits protection against Ebola Virus Disease (EVD). In a study of forty-eight healthy adult volunteers who received either the rVSVΔG-ZEBOV-GP vaccine or placebo, we profiled intracellular microRNAs (miRNAs) from whole blood cells (WB) and circulating miRNAs from serum-derived extracellular vesicles (EV) at baseline and longitudinally following vaccination. Further, we identified early miRNA signatures associated with ZEBOV-specific IgG antibody responses at baseline and up to one year post-vaccination, and pinpointed target mRNA transcripts and pathways correlated to miRNAs whose expression was altered after vaccination by using systems biology approaches.Several miRNAs were differentially expressed (DE) and miRNA signatures predicted high or low IgG ZEBOV-specific antibody levels with high classification performance. The top miRNA discriminators were WB-miR-6810, EV-miR-7151-3p, and EV-miR-4426. An eight-miRNA antibody predictive signature was associated with immune-related target mRNAs and pathways.These findings provide valuable insights into early blood biomarkers associated with rVSVΔG-ZEBOV-GP vaccine-induced IgG antibody responses.
